David Happel

CIK: 0001623567

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SGMT

Sagimet Biosciences Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

SGMT
Sagimet Biosciences Inc.
Jul 20, 2026
Sale(S)
Direct
64.1K shares at avg. $7.76$497K
SGMT
Sagimet Biosciences Inc.
May 28, 2026
Award(A)
Stock Option (Right to Buy)
Direct
300K shares-
SGMT
Sagimet Biosciences Inc.
Feb 19, 2026
Award(A)
Direct
128K shares-
SGMT
Sagimet Biosciences Inc.
Feb 10, 2026
Sale(S)
Direct
12.1K shares at avg. $5.36$65K
SGMT
Sagimet Biosciences Inc.
Jul 21, 2025
Sale(S)
Direct
65.5K shares at avg. $9.13$598K
SGMT
Sagimet Biosciences Inc.
Feb 6, 2025
Award(A)
Direct
116K shares-

		Type	Shares	Price		Ownership
Jul 20, 2026	SGMT Sagimet Biosciences Inc.	Sale(S)	64,051	$7.76	$497,068	Direct
May 28, 2026	SGMT Sagimet Biosciences Inc.	Award(A) Stock Option (Right to Buy)	300,000	-	-	Direct
Feb 19, 2026	SGMT Sagimet Biosciences Inc.	Award(A)	128,000	-	$0	Direct
Feb 10, 2026	SGMT Sagimet Biosciences Inc.	Sale(S)	12,101	$5.36	$64,865	Direct
Jul 21, 2025	SGMT Sagimet Biosciences Inc.	Sale(S)	65,478	$9.13	$598,115	Direct
Feb 6, 2025	SGMT Sagimet Biosciences Inc.	Award(A)	116,000	-	-	Direct

1-6 of 6 transactions

About Happel David

Happel David (SEC CIK 0001623567) files insider reports with the SEC as President & CEO of Sagimet Biosciences Inc. (SGMT).

Signal8 holds 6 ownership filings by Happel David, all Form 4s, filed between Feb 7, 2025 and Jul 22, 2026. Those filings report 6 transactions, from Feb 6, 2025 to Jul 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Happel David's filings is in FOSTER CITY, CA.

Recent filings by Happel David

Jul 20, 2026: Open-market sale of SGMT shares (Form 4, code S).
May 28, 2026: Grant or award of SGMT derivative securities (Form 4, code A).
Feb 19, 2026: Grant or award of SGMT shares (Form 4, code A).
Feb 10, 2026: Open-market sale of SGMT shares (Form 4, code S).
Jul 21, 2025: Open-market sale of SGMT shares (Form 4, code S).

Other insiders filing for Sagimet Biosciences Inc. (SGMT)

Kemble George, Director
Rozek Elizabeth, Chief Legal & Admin. Officer
SEIDENBERG BETH C, Director
Hoelscher Paul W., Director
Jarrett Jennifer, Director
GRAMMER ELIZABETH A, Director

How to read Form 4 transaction codes